Staurosporine | 星孢菌素 | STS | PKC/PKA Inhibitor | AmBeed-信号通路专用抑制剂

首页 / / / / Staurosporine

星形孢菌素 /Staurosporine {[allProObj[0].p_purity_real_show]}

货号：A256460 同义名： 星孢菌素 / STS;AM-2282

Staurosporine is a prototypical potent ATP-competitive multikinase inhibitor with IC50 of 0.7, 7, 8.5, 6, 20 nM for PKC, PKA,PKG, p60v-src tyrosine protein kinase, CaM kinase II, respectively.

Staurosporine 化学结构
CAS号：62996-74-1

Staurosporine 3D分子结构
CAS号：62996-74-1

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_am, item.pr_size) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]}	现货	咨询	- +

购物车0 收藏询单

sales@ambeed.cn tech@ambeed.cn 400-920-2911 产品手册产品订购技术咨询
快速发货顺丰冷链运输，1-2 天到达

品质保证

技术支持

免费溶解

Staurosporine 纯度/质量文件产品仅供科研

货号：A256460 标准纯度： {[allProObj[0].p_purity_real_show]} 产品说明书

批次查询：批次纯度: COA SDS NMR HPLC CNMR LC-MS

全球学术期刊中引用的产品: • Nat. Biomed. Eng., 2024, 8, 1412-1424. Ambeed. [ A538667 , A631746 ]; • JMC, 2024. Ambeed. [ A833302 , A475501 , A341986 , A356070 ]; • BMC Cancer, 2024, 24(1): 1415. Ambeed. [ A809692 , A209020 ]; • J. Am. Soc. Mass Spectrom., 2024, 35(12): 3192-3202. Ambeed. [ A166127 , A902473 , A753371 , A961334 , A292945 , A230770 , A300620 , A1114580 , A1159765 , A206238 ]; • PloS One, 2024, 19(11): e0308060. Ambeed. [ A302917 ]; 更多 >

PKC 亚型比较
转化生长因子-β 亚型比较

产品名称	PKC ↓ ↑	PKCα ↓ ↑	PKCβ ↓ ↑	PKCγ ↓ ↑	PKCδ ↓ ↑	PKCε ↓ ↑	PKCζ ↓ ↑	PKCη ↓ ↑	PKCθ ↓ ↑	其他靶点	纯度
Daphnetin	+ PKC, IC50: 25.01 μM									PKA,EGFR	95%
Dequalinium Chloride											99%+
Quercetin	✔									Sirtuin,Src	97%
Myricetrin		✔									96%
Go 6983		+++ PKCα, IC50: 7 nM	+++ PKCβ, IC50: 7 nM	+++ PKCγ, IC50: 6 nM	+++ PKCδ, IC50: 10 nM		++ PKCζ, IC50: 60 nM				99%+
Go6976	+++ PKC, IC50: 7.9 nM	++++ PKCα, IC50: 2.3 nM	+++ PKCβ1, IC50: 6.2 nM							FLT3	99%+
Bisindolylmaleimide I		+++ PKCα, IC50: 20 nM	+++ PKCβ1, IC50: 17 nM PKCβ2, IC50: 16 nM	+++ PKCγ, IC50: 20 nM							99%+
Lawsone methyl ether			✔								99%
Sotrastaurin		++++ PKCα, Ki: 0.95 nM	++++ PKCβ1, Ki: 0.64 nM		++++ PKCδ, Ki: 2.1 nM	++++ PKCε, Ki: 3.2 nM		++++ PKCη, Ki: 1.8 nM	++++ PKCθ, Ki: 0.22 nM		99%+
Enzastaurin		++ PKCα, IC50: 39 nM	+++ PKCβ, IC50: 6 nM	+ PKCγ, IC50: 83 nM		+ PKCε, IC50: 110 nM					98%
Midostaurin		++ PKCα, IC50: 22 nM	++ PKCβ1, IC50: 30 nM PKCβ2, IC50: 31 nM	++ PKCγ, IC50: 24 nM	+ PKCδ, IC50: 330 nM	+ PKCε, IC50: 1.25 μM		+ PKCη, IC50: 160 nM			99%
Ro 31-8220 mesylate		++++ PKCα, IC50: 5 nM	+++ PKCβ1, IC50: 24 nM PKCβ2, IC50: 14 nM	++ PKCγ, IC50: 27 nM		++ PKCε, IC50: 24 nM					99%+
Staurosporine		++++ PKCα, IC50: 2 nM		++++ PKCγ, IC50: 5 nM	+++ PKCδ, IC50: 20 nM	++ PKCε, IC50: 73 nM		++++ PKCη, IC50: 4 nM			99%+
Ruboxistaurin HCl		+ PKCα, IC50: 0.36 μM	++++ PKCβ1, IC50: 4.7 nM PKCβ2, IC50: 5.9 nM	+ PKCγ, IC50: 0.3 μM	+ PKCδ, IC50: 0.25 μM			++ PKCη, IC50: 0.052 μM			99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

产品名称	ALK1 ↓ ↑	ALK2 ↓ ↑	ALK3 ↓ ↑	ALK4 ↓ ↑	ALK6 ↓ ↑	Smad3 ↓ ↑	TGF-β ↓ ↑	TGFβRI/ALK5 ↓ ↑	TGFβRII ↓ ↑	纯度
LDN193189	++++ ALK1, IC50: 0.8 nM	++++ ALK2, IC50: 0.8 nM	+++ ALK3, IC50: 5.3 nM		+++ ALK6, IC50: 16.7 nM					99%+
LDN-212854	++++ ALK1, IC50: 2.4 nM	++++ ALK2, IC50: 1.3 nM	+ ALK3, IC50: 85.8 nM	+ ALK4, IC50: 2133 nM				+ ALK5, IC50: 9276 nM		99%+
ML347	++ ALK1, IC50: 46 nM	++ ALK2, IC50: 32 nM								98%
K02288	++++ ALK1, IC50: 1.8 nM	++++ ALK2, IC50: 1.1 nM	++ ALK3, IC50: 34.4 nM		+++ ALK6, IC50: 6.4 nM					99%+
LDN-193189 dihydrochloride	++++ ALK1, IC50: 0.8 nM	++++ ALK2, IC50: 0.8 nM	+++ ALK3, IC50: 5.3 nM		+++ ALK6, IC50: 16.7 nM					99%
LDN-214117		++ ALK2, IC50: 24 nM								98%
DMH-1		+ ALK2, IC50: 107.9 nM								99%+
SB-505124				+ ALK4, IC50: 129 nM				++ ALK5, IC50: 47 nM		99%+
Vactosertib				+++ ALK4, IC50: 13 nM				+++ ALK5, IC50: 11 nM		99%+
Alantolactone						✔				98%
SIS3						✔				97%
Pirfenidone							✔			98%
Hesperetin							✔			97%
RepSox								++++ TGFβR1(ALK5), IC50: 4 nM		98%
GW788388								+++ ALK5, IC50: 18 nM		98%
LY364947								++ TGFβRI, IC50: 59 nM	+ TGFβRII, IC50: 0.4 μM	98%
SD-208								++ TGF-βRI (ALK5), IC50: 48 nM		98%
SB-525334								+++ TGFβR1(ALK5), IC50: 14.3 nM		99%+
LY2109761								++ TβRI, Ki: 38 nM	+ TβRII, Ki: 300 nM	99%+
Galunisertib								++ TβRI, IC50: 56 nM		98%
SB 431542								+ ALK5, IC50: 94 nM		99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

Staurosporine 生物活性

靶点	PKCη PKCη, IC50:4 nM PKCγ PKCγ, IC50:5 nM PKCε PKCε, IC50:73 nM PKCα PKCα, IC50:2 nM PKCδ PKCδ, IC50:20 nM
描述	Protein kinase C (PKC) is a serine/threonine protein kinase, which plays a crucial role in signaling transduction mechanisms in many cell types and tissues. Staurosporine is the first reported and widely used PKC inhibitor with IC50 value of 2.7 nM for PKC (rat brain, measured by enzyme activity assay)^[1] and also displays broadly potent across the kinome with IC50 values of 15 nM, 18 nM, 3 nM, 5 nM, 21 nM, 20 nM, 9 nM, 6 nM, 20 nM, 2 nM, 16 nM for PKA, PKG, Phosphorylase kinase, S6 kinase, MLCK, Ca²⁺/CaM PK-II, cdc2, v-Src, Lyn, c-Fgr, TPK-IIB/Syk (measured by recombinant enzyme), respectively. Staurosporine is a broad selective protein kinase inhibitor and can suppress the auto-phosphorylation of Lyn and c-Fgr in a dose-dependent manner^[2]. Staurosporine induces the translocation of PKC from the soluble to the membrane, considered as the inactivation of PKC, and causes the Inhibition of PKC activity with decreased phosphorylation of PKC substrate. The inhibition of staurosporine against PKC is Ca²⁺ dependent^[3]. Staurosporine can disturb different cell response, including neuronal function, cell growth and differentiation, cell motility, secretion and cellular metabolism and smooth muscle contraction, through inhibition of PKC^[4].
作用机制	Staurosporine is an ATP-competitive inhibitor of PKC^[2].

Staurosporine 细胞研究

细胞系	浓度	检测类型	检测时间	活动说明	数据源
FL5.12-Akt1 cells		Proliferation assay		Antiproliferative activity against FL5.12-Akt1 cells by MTT assay, IC50=0.29 μM.	16403626
HEK293 cells		Cytotoxic assay	72 h	Cytotoxicity against HEK293 cells after 72 hrs by CellTiterGlo assay, IC50=56 nM.	24763262
HEK293 cells		Function assay		Inhibition of IL-8 release by HEK293 cells expressing PKC-beta2, IC50=77 nM.	15771419
HEK293 cells		Cytotoxic assay		Cytotoxicity against HEK293 cells, EC50=2 μM.	25316317

Staurosporine 动物研究

Dose

Rat^[5] (i.v.): min = 0.1 mg/kg, max = 10 mg/kg

Administration

i.v.

Pharmacokinetics

Animal	Rats^[6]
T_1/2	51.6 min (in plasma) 75.3 min (in RBC)

Staurosporine 临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT00651261	Leukemia	Phase 3	Active, not recruiting	-	-
NCT01161550	Leukemia, Myeloid, Acute	Phase 1	Completed	-	United States, Missouri ... 展开 >> Washington University School of Medicine St. Louis, Missouri, United States, 63110 收起 <<
NCT00019838	Leukemia Lymp... 展开 >>homa 收起 <<	Phase 1	Completed	-	United States, Maryland ... 展开 >> Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support Bethesda, Maryland, United States, 20892-1182 NCI - Center for Cancer Research Bethesda, Maryland, United States, 20892 收起 <<

Staurosporine 参考文献

[1]Tamaoki T, Nomoto H, et al. Staurosporine, a potent inhibitor of phospholipid/Ca++dependent protein kinase. Biochem Biophys Res Commun. 1986 Mar 13;135(2):397-402.

[2]Meggio F, Donella Deana A, et al. Different susceptibility of protein kinases to staurosporine inhibition. Kinetic studies and molecular bases for the resistance of protein kinase CK2. Eur J Biochem. 1995 Nov 15;234(1):317-22.

[3]Wolf M, Baggiolini M, et al. The protein kinase inhibitor staurosporine, like phorbol esters, induces the association of protein kinase C with membranes. Biochem Biophys Res Commun. 1988 Aug 15;154(3):1273-9.

[4]Ōmura S, Asami Y, et al. Staurosporine: new lease of life for parent compound of today's novel and highly successful anti-cancer drugs. J Antibiot (Tokyo). 2018 Aug;71(8):688-701.

[5]Secrest RJ, Williams P, et al. Hypotensive properties of the protein kinase inhibitor, staurosporine, in normotensive and spontaneously hypertensive rats. Clin Exp Hypertens A. 1991;13(2):219-34.

[6]Gurley LR, Umbarger KO, et al. High-performance liquid chromatographic analysis of staurosporine in vivo. Its translocation and pharmacokinetics in rats. J Chromatogr B Biomed Sci Appl. 1998 Aug 7;712(1-2):211-24.

Staurosporine 实验方案

计算器

存储液制备

1mg

5mg

10mg

1 mM

5 mM

10 mM

2.14mL

0.43mL

0.21mL

10.72mL

2.14mL

1.07mL

21.43mL

4.29mL

2.14mL

Staurosporine 技术信息

CAS号	62996-74-1
分子式	C₂₈H₂₆N₄O₃
分子量	466.531

别名	星孢菌素 ;STS;AM-2282;Staurosporin.;CGP-39360;CGP 41251;Antibiotic 230;Stsp;AM-2282，Antibiotic AM-2282;Antibiotic AM-2282
运输	蓝冰

存储条件

液体 -20°C:3-6个月-80°C:12个月

粉末 Keep in dark place,Inert atmosphere,2-8°C

溶解度

DMSO: 60 mg/mL(128.61 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

动物实验配方

IP 2% DMSO+2% Tween80+30% PEG300+water 1.8 mg/mL clear

PO 0.5% CMC-Na 35 mg/mL suspension

大规格询价

* 公司或机构名称：

* 姓名：

* 电话：

* 邮箱： * 国家/区域： * 需求量：

* 货号：

* CAS号：

* 产品名称：在线留言：

请填写此表格索取QC报告。我们很快就会发送到您的邮箱。您的信息在我们这里是安全的。*是必填项.

产品名称： * 货号：

* 姓名：

* 电话：

* 邮箱： * 公司或机构名称： * 部门：留言给我们：

摩尔计算器

计算溶液所需的质量，体积或浓度。 Ambeed 摩尔浓度计算器基于以下方程式：

浓度 (mol/L) × 体积 (L) × 分子量 (g/mol)=质量 (g)

浓度

体积

分子量

质量

*在制备母液时，请始终参考产品标签或 MSDS / COA（在产品页面可下载）上所显示的对应批次产品的分子量。

靶点

靶点	数值

PKCη	PKCη, IC50:4 nM
PKCγ	PKCγ, IC50:5 nM
PKCε	PKCε, IC50:73 nM
PKCα	PKCα, IC50:2 nM
PKCδ	PKCδ, IC50:20 nM

总药量计算器

动物实验：给药剂量 mg/kg 动物体重 g 动物数量只每天给药次给药天

需要的总药量： mg

工作液计算器

动物实验：给药剂量 mg/kg 动物体重 g 给药体积 μL

您需要配制的工作液浓度为：mg/mL

细胞研究

细胞系	浓度	检测类型	检测时间	活动说明	数据源

FL5.12-Akt1 cells	Proliferation assay		Antiproliferative activity against FL5.12-Akt1 cells by MTT assay, IC50=0.29 μM.	16403626
HEK293 cells	Cytotoxic assay	72 h	Cytotoxicity against HEK293 cells after 72 hrs by CellTiterGlo assay, IC50=56 nM.	24763262
HEK293 cells	Function assay		Inhibition of IL-8 release by HEK293 cells expressing PKC-beta2, IC50=77 nM.	15771419
HEK293 cells	Cytotoxic assay		Cytotoxicity against HEK293 cells, EC50=2 μM.	25316317
HUE cells	Function assay	90 mins	Inhibition of VEGFR2 in HUE cells assessed as inhibition of VEGF-induced autophosphorylation treated for 90 mins before VEGF challenge by ELISA, IC50=70 nM.	20170163
human 518A2 cells	Cytotoxic assay	96 h	Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay， IC50=0.2 μM.	24361521
human 8505C cells	Cytotoxic assay	96 h	Cytotoxicity against human 8505C cells after 96 hrs by SRB assay, IC50=0.2 μM.	24361521
human A2780 cells	Cytotoxic assay	96 h	Cytotoxicity against human A2780 cells after 96 hrs by SRB assay, IC50=0.2 μM.	24361521
human A431 cells	Cytotoxic assay	24 h	Cytotoxicity against human A431 cells after 24 hrs using Annexin VeFITC/propidium iodide staining by MTT assay, IC50=70 nM.	22541051
human A549 cells	Cytotoxic assay	72 h	Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B method	18484775
human A549 cells	Cytotoxic assay	48 h	Cytotoxicity against human A549 cells after 48 hrs by MTT assay , IC50=20 nM.	25825934
human A549 cells	Cytotoxic assay	96 h	Cytotoxicity against human A549 cells after 96 hrs by SRB assay, IC50=0.6 μM.	24361521
human BGC823 cells	Cytotoxic assay	72 h	Cytotoxicity against human BGC823 cells after 72 hrs by CellTitre-Glo luminescent cell viability assay, IC50=0.38 μM.	24328283
human BJ cells	Cytotoxic assay	72 h	Cytotoxicity against human BJ cells after 72 hrs by Calcein AM assay, IC50=0.002 μM.	22921081
human BJ cells	Cytotoxic assay		Cytotoxicity against human BJ cells, EC50=2 μM.	25316317
human CEM cells	Cytotoxic assay	72 h	Cytotoxicity against human CEM cells after 72 hrs by Calcein AM assay, IC50=23 nM.	22921081
human CHOK1 cells	Cytotoxic assay	48 h	Cytotoxicity against human CHOK1 cells after 48 hrs by SRB assay， IC50=0.13 μM.	21513294
human colon cancer cell line (LoVo cells)	Proliferation assay		Antiproliferative activity against human colon cancer cell line (LoVo cells) using MTT assay, IC50=0.001 μM.	11591505
human colon carcinoma cell line HCT116	Function assay		Concentration required for growth inhibition of human colon carcinoma cell line HCT116, IC50=6 nM.	15537345
human DLD1 cells	Proliferation assay	48-72 h	Antiproliferative activity against human DLD1 cells after 48 to 72 hrs by MTT assay, IC50=9 nM.	22182929
human HeLa cells	Cytotoxic assay	48 h	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay, IC50=4e-06 μM.	21388191
human HeLa cells	Cytotoxic assay	48 h	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay, IC50=25 nM.	25825934
human HepG2 cells	Cytotoxic assay		Cytotoxicity against human HepG2 cells, EC50=2 μM.	25316317
human HT-29 cells	Function assay	2 h	Effect on mitochondrial membrane potential in human HT-29 cells after 2 hrs using JC-1 staining by fluorescence assay	21428375
human HT-29 cells	Function assay		Inhibition of mitochondrial membrane potential in human HT-29 cells using JC1 dye staining by fluorescence plate reader assay, IC50=2.5 nM	21513293
human HT-29 cells	Function assay	2 h	Induction of apoptosis in human HT-29 cells assessed reduction of mitochondrial membrane potential after 2 hrs by using JC1 staining by fluorescence cell-based assay, EC50=2.6 nM.	21973101
human HuH7 cells	Cytotoxic assay	72 h	Cytotoxicity against human HuH7 cells after 72 hrs by CellTitre-Glo luminescent cell viability assay, IC50=0.23 μM.	24328283
human HUVEC	Proliferation assay	48 to 72 h	Antiproliferative activity against human HUVEC after 48 to 72 hrs by MTT assay	22182929
human Jurkat cells	Proliferation assay		Antiproliferative activity against JAK3 expressing IL2-stimulated human Jurkat cells, IC50=71 nM.	19427203
human KE-97 cells	Cytotoxic assay	72 h	Cytotoxicity against human KE-97 cells after 72 hrs by CellTitre-Glo luminescent cell viability assay, IC50=0.13 μM.	24328283
human LoVo cells	Proliferation assay	48 to 72 h	Antiproliferative activity against human LoVo cells after 48 to 72 hrs by MTT assay	22182929
human MCF7 cells	Cytotoxic assay	48 h	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay, IC50=50 nM.	21388191
human MCF7 cells	Cytotoxic assay	96 h	Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay, IC50=0.4 μM.	24361521
human MDA-MB-231 cells	Cytotoxic assay	72 h	Cytotoxicity against human MDA-MB-231 cells after 72 hrs by sulforhodamine B method, GI50=7.1 nM.	18484775
human MiaPaCa-2 cells	Proliferation assay		Antiproliferative activity against human MiaPaCa-2 cells, IC50=0.37 μM.	16413780
human PBMC	Function assay	24 h	Suppression of IL2 production in human PBMC after 24 hrs by ELISA, IC50=16 nM.	18585046
human PC3 cells	Cytotoxic assay	48 h	Cytotoxicity against human PC3 cells after 48 hrs by MTT assay , IC50=31 nM.	25825934
human Raji cells	Cytotoxic assay		Cytotoxicity against human Raji cells, EC50=2 μM.	25316317
human SF268 cells	Cytotoxic assay	48 h	Cytotoxicity against human SF268 cells after 48 hrs by SRB assay, GI50=44 nM.	21513294
human ST486 cells	Proliferation assay	48 to 72 h	Antiproliferative activity against human ST486 cells after 48 to 72 hrs by MTT assay, IC50=7 nM.	22182929
human U937 cells	Cytotoxic assay		Cytotoxicity against human U937 cells, IC50=2 μM.	17088067
insect cells	Function assay		Inhibition of human recombinant Pim1 expressed in insect cells by HTRF, IC50=10 nM.	19179076
mouse NIH/3T3 cells	Cytotoxic assay	96 h	Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay, IC50=0.2 μM.	24361521
P19 cells	Function assay		Inhibition of Platelet-derived growth factor receptor in P19 cells, IC50=0.002 μM.	15771419
P19 cells	Function assay		Inhibition of Protein Kinase A in P19 cells, IC50=4 nM.	15771419
P19 cells	Function assay		Inhibition of Cyclin-dependent kinase 1 in P19 cells, IC50=8 nM.	15771419
P19 cells	Function assay		Inhibition of Vascular endothelial growth factor receptor in P19 cells, IC50=14 nM.	15771419
Sf21 cells	Function assay		Inhibition of JAK3 expressed in Sf21 cells, IC50=6 nM.	17088059
Sf9 cells	Function assay		Inhibition of human Syk expressed in Sf9 cells, IC50=3 nM.	18823784
Sf9 cells	Function assay		Inhibition of human Fyn expressed in Sf9 cells after 1 min by ELISA in presence of 1 umol/L ATP	17315853
Sf9 cells	Function assay	20 mins	Inhibition of human Fyn expressed in Sf9 cells after 20 mins by ELISA in presence of 1 umol/L ATP, IC50=15 nM.	17315853
V79 MZ cells	Function assay		Inhibition of human aldosterone synthase expressed in V79 MZ cells assessed as inhibition of aldosterone synthesis, IC50=11 nM.	24422519

临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT00651261	Leukemia	Phase 3	Active, not recruiting	-	-
NCT01161550	Leukemia, Myeloid, Acute	Phase 1	Completed	-	United States, Missouri ... 展开 >> Washington University School of Medicine St. Louis, Missouri, United States, 63110 收起 <<
NCT00019838	Leukemia Lymp... 展开 >>homa 收起 <<	Phase 1	Completed	-	United States, Maryland ... 展开 >> Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support Bethesda, Maryland, United States, 20892-1182 NCI - Center for Cancer Research Bethesda, Maryland, United States, 20892 收起 <<
NCT00651261	-		Active, not recruiting	-	-
NCT02115295	Leukemia	Phase 2	Recruiting	May 2019	United States, Texas ... 展开 >> University of Texas MD Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 收起 <<
NCT01754441	-		Unknown	December 2017	United States, Delaware ... 展开 >> Alfred I. duPont Hospital for Children Wilmington, Delaware, United States, 19803 United States, Florida Nemours Children's Specialty Care, Jacksonville Jacksonville, Florida, United States, 32207 Nemours Children's Hospital Orlando, Florida, United States, 32827 收起 <<
NCT03512197	Acute Myeloid Leukemia (AML)	Phase 3	Recruiting	April 20, 2026	-
NCT03092674	Acute Myeloid Leukemia ... 展开 >> Myelodysplastic Syndrome Myelodysplastic Syndrome With Excess Blasts-2 Untreated Adult Acute Myeloid Leukemia 收起 <<	Phase 2 Phase 3	Suspended(Other - Safety data ... 展开 >>review, unscheduled) 收起 <<	August 1, 2023	-
NCT03591510	FLT3-mutated Acute Myeloid Leu... 展开 >>kemia 收起 <<	Phase 2	Not yet recruiting	April 21, 2025	Korea, Republic of ... 展开 >> Novartis Investigative Site Seoul, Korea, Republic of, 03080 收起 <<
NCT00042861	Unspecified Adult Solid Tumor,... 展开 >> Protocol Specific 收起 <<	Phase 1	Completed	-	United States, Maryland ... 展开 >> Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support Bethesda, Maryland, United States, 20892-1182 收起 <<
NCT00031681	Advanced Adult Primary Liver C... 展开 >>ancer Carcinoma of the Appendix Estrogen Receptor-negative Breast Cancer Extensive Stage Small Cell Lung Cancer Gastrointestinal Stromal Tumor HER2-negative Breast Cancer Metastatic Gastrointestinal Carcinoid Tumor Ovarian Sarcoma Ovarian Stromal Cancer Progesterone Receptor-negative Breast Cancer Recurrent Adenoid Cystic Carcinoma of the Oral Cavity Recurrent Adult Primary Liver Cancer Recurrent Anal Cancer Recurrent Basal Cell Carcinoma of the Lip Recurrent Borderline Ovarian Surface Epithelial-stromal Tumor Recurrent Breast Cancer Recurrent Cervical Cancer Recurrent Colon Cancer Recurrent Endometrial Carcinoma Recurrent Esophageal Cancer Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity Recurrent Extrahepatic Bile Duct Cancer Recurrent Gallbladder Cancer Recurrent Gastric Cancer Recurrent Gastrointestinal Carcinoid Tumor Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity Recurrent Lymphoepithelioma of the Nasopharynx Recurrent Lymphoepithelioma of the Oropharynx Recurrent Metastatic Squamous Neck Cancer With Occult Primary Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity Recurrent Mucoepidermoid Carcinoma of the Oral Cavity Recurrent Non-small Cell Lung Cancer Recurrent Ovarian Epithelial Cancer Recurrent Ovarian Germ Cell Tumor Recurrent Pancreatic Cancer Recurrent Prostate Cancer Recurrent Rectal Cancer Recurrent Salivary Gland Cancer Recurrent Small Cell Lung Cancer Recurrent Small Intestine Cancer Recurrent Squamous Cell Carcinoma of the Hypopharynx Recurrent Squamous Cell Carcinoma of the Larynx Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity Recurrent Squamous Cell Carcinoma of the Nasopharynx Recurrent Squamous Cell Carcinoma of the Oropharynx Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity Recurrent Verrucous Carcinoma of the Larynx Recurrent Verrucous Carcinoma of the Oral Cavity Small Intestine Adenocarcinoma Small Intestine Leiomyosarcoma Small Intestine Lymphoma Stage IV Adenoid Cystic Carcinoma of the Oral Cavity Stage IV Anal Cancer Stage IV Basal Cell Carcinoma of the Lip Stage IV Borderline Ovarian Surface Epithelial-stromal Tumor Stage IV Breast Cancer Stage IV Colon Cancer Stage IV Endometrial Carcinoma Stage IV Esophageal Cancer Stage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity Stage IV Gastric Cancer Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity Stage IV Lymphoepithelioma of the Nasopharynx Stage IV Lymphoepithelioma of the Oropharynx Stage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity Stage IV Mucoepidermoid Carcinoma of the Oral Cavity Stage IV Non-small Cell Lung Cancer Stage IV Ovarian Epithelial Cancer Stage IV Ovarian Germ Cell Tumor Stage IV Pancreatic Cancer Stage IV Prostate Cancer Stage IV Rectal Cancer Stage IV Salivary Gland Cancer Stage IV Squamous Cell Carcinoma of the Hypopharynx Stage IV Squamous Cell Carcinoma of the Larynx Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity Stage IV Squamous Cell Carcinoma of the Nasopharynx Stage IV Squamous Cell Carcinoma of the Oropharynx Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity Stage IV Verrucous Carcinoma of the Larynx Stage IV Verrucous Carcinoma of the Oral Cavity Stage IVA Cervical Cancer Stage IVB Cervical Cancer Triple-negative Breast Cancer Unresectable Extrahepatic Bile Duct Cancer Unresectable Gallbladder Cancer Unspecified Adult Solid Tumor, Protocol Specific Untreated Metastatic Squamous Neck Cancer With Occult Primary 收起 <<	Phase 1	Completed	-	United States, Virginia ... 展开 >> University of Virginia Charlottesville, Virginia, United States, 22908 收起 <<
NCT00045513	Leukemia Lymp... 展开 >>homa 收起 <<	Phase 1 Phase 2	Completed	-	Canada, Ontario ... 展开 >> McMaster Children's Hospital at Hamilton Health Sciences Hamilton, Ontario, Canada, L8N 3Z5 London Health Sciences Centre London, Ontario, Canada, N6A 465 Princess Margaret Hospital at University Health Network Toronto, Ontario, Canada, M5G 2M9 收起 <<
NCT00045942	-		Completed	-	-
NCT00819546	Acute Myeloid Leukemia ... 展开 >> Myelodysplastic Syndrome 收起 <<	Phase 1	Active, not recruiting	December 2019	United States, Massachusetts ... 展开 >> Massachusetts General Hospital Boston, Massachusetts, United States, 02114 Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02115 Beth Israel Deaconess Medical Center Boston, Massachusetts, United States, 02215 收起 <<
NCT00047242	Unspecified Adult Solid Tumor,... 展开 >> Protocol Specific 收起 <<	Phase 1	Completed	-	United States, Maryland ... 展开 >> Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Baltimore, Maryland, United States, 21231-2410 收起 <<
NCT01477606	Acute Myeloid Leukemia	Phase 2	Active, not recruiting	June 2020	-
NCT03280030	Acute Myeloid Leukemia	Phase 2	Recruiting	June 20, 2022	Hong Kong ... 展开 >> Novartis Investigative Site Recruiting Hong Kong, Hong Kong Japan Novartis Investigative Site Recruiting Nagoya-city, Aichi, Japan, 466-8650 Novartis Investigative Site Recruiting Toyoake city, Aichi, Japan, 470 1192 Novartis Investigative Site Recruiting Kashiwa, Chiba, Japan, 277-8577 Novartis Investigative Site Recruiting Matsuyama-city, Ehime, Japan, 790-8524 Novartis Investigative Site Recruiting Fukuoka city, Fukuoka, Japan, 812-8582 Novartis Investigative Site Recruiting Fukuyama city, Hiroshima, Japan, 720-0001 Novartis Investigative Site Recruiting Isehara-city, Kanagawa, Japan, 259-1193 Novartis Investigative Site Recruiting Kochi city, Kochi, Japan, 781-8555 Novartis Investigative Site Recruiting Nagasaki-city, Nagasaki, Japan, 852-8501 Novartis Investigative Site Recruiting Sayama, Osaka, Japan, 589 8511 Novartis Investigative Site Recruiting Shimotsuke city, Tochigi, Japan, 329-0498 Novartis Investigative Site Recruiting Bunkyo-ku, Tokyo, Japan, 113-8677 Novartis Investigative Site Recruiting Shinagawa-ku, Tokyo, Japan, 141 8625 Korea, Republic of Novartis Investigative Site Recruiting Seoul, Korea, Republic of, 03722 Taiwan Novartis Investigative Site Recruiting Putzu City, Chiayi Hsien, Taiwan, 61363 Novartis Investigative Site Recruiting Kaohsiung City, Taiwan, 83301 Novartis Investigative Site Recruiting Taipei, Taiwan, 10002 Novartis Investigative Site Recruiting Taoyuan, Taiwan, 33305 收起 <<
NCT00093600	Acute Myeloid Leukemia (AML)	Phase 1	Completed	-	United States, California ... 展开 >> Jonsson Comprehensive Cancer Center at UCLA Los Angeles, California, United States, 90095-1781 United States, Massachusetts Dana Faber Cancer Institute Boston, Massachusetts, United States, 02115 United States, Michigan Wayne State University/Karmanos Cancer Institute Detroit, Michigan, United States, 48201-2014 United States, Texas MD Anderson Cancer Center/University of Texas Houston, Texas, United States, 77030 Germany Novartis Investigative Site Dresden, Germany Novartis Investigative Site Mainz, Germany 收起 <<
NCT00045942	Acute Myeloid Leukemia ... 展开 >> Myelodysplastic Syndromes 收起 <<	Phase 1 Phase 2	Completed	-	United States, California ... 展开 >> UCLA Medical Center Los Angeles, California, United States, 90095 United States, Massachusetts Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02115 United States, New York New York Weill Cornell Medical Center New York, New York, United States, 10021 Memorial Sloan Kettering Cancer Center New York, New York, United States, 10065 收起 <<
NCT03760445	Leukemia, Myeloid, Acute	Phase 1 Phase 2	Not yet recruiting	October 13, 2022	-
NCT00036777	Unspecified Adult Solid Tumor,... 展开 >> Protocol Specific 收起 <<	Phase 1	Completed	-	United States, Maryland ... 展开 >> University of Maryland Greenebaum Cancer Center Baltimore, Maryland, United States, 21201-1595 收起 <<
NCT01130662	Acute Myeloid Leukemia	Phase 1	Completed	-	United States, Kansas ... 展开 >> University of Kansas Medical Center, Westwood Campus Kansas City, Kansas, United States, 66205 收起 <<
NCT00012194	Unspecified Adult Solid Tumor,... 展开 >> Protocol Specific 收起 <<	Phase 1	Terminated	-	United States, New Hampshire ... 展开 >> Dartmouth Hitchcock Medical Center Lebanon, New Hampshire, United States, 03756 收起 <<
NCT00045175	Fallopian Tube Cancer ... 展开 >> Ovarian Cancer Primary Peritoneal Cavity Cancer 收起 <<	Phase 1	Completed	-	Canada, Ontario ... 展开 >> Margaret and Charles Juravinski Cancer Centre Hamilton, Ontario, Canada, L8V 5C2 Cancer Care Ontario-London Regional Cancer Centre London, Ontario, Canada, N6A 4L6 Princess Margaret Hospital Toronto, Ontario, Canada, M5G 2M9 收起 <<
NCT00039403	Adenocarcinoma of the Pancreas... 展开 >> Recurrent Pancreatic Cancer Stage II Pancreatic Cancer Stage III Pancreatic Cancer Stage IV Pancreatic Cancer 收起 <<	Phase 1	Completed	-	United States, Texas ... 展开 >> M D Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT03258931	Newly Diagnosed FLT3 Mutated A... 展开 >>ML 收起 <<	Phase 3	Recruiting	November 2024	United States, California ... 展开 >> US Davis Health Recruiting Sacramento, California, United States, 95817 Contact: Brian Jonas, MD 800-282-3284 bajonas@ucdavis.edu United States, Florida Moffitt Cancer Center Recruiting Tampa, Florida, United States, 33612 Contact: Kendra Sweet, MD 813-745-6841 Kendra.Sweet@moffitt.org United States, Kansas University of Kansas Recruiting Kansas City, Kansas, United States, 66160 Contact: Sunil Abhyankar, MD 913-588-9281 sabhyankar@kumc.edu United States, Massachusetts Dana-Farber Cancer Insitute Recruiting Boston, Massachusetts, United States, 02215 Contact: Richard M Stone, MD 617-632-2214 Richard_Stone@dfci.harvard.edu United States, Michigan Karmanos Cancer Institute Recruiting Detroit, Michigan, United States, 48201 Contact: Jay Yang, MD 800-527-6266 yangj@karmanos.org Henry Ford Health System Recruiting Detroit, Michigan, United States, 48202 Contact: Yue Guo, MD 800-436-7936 YGUO1@hfhs.org United States, New York Roswell PArk Recruiting Buffalo, New York, United States, 14263 Contact: Eunice S Wang, MD 716-845-3544 eunice.wang@roswellpark.org 收起 <<
NCT00045500	Lymphoma Unsp... 展开 >>ecified Adult Solid Tumor, Protocol Specific 收起 <<	Phase 1	Completed	-	United States, Maryland ... 展开 >> Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support Bethesda, Maryland, United States, 20892-1182 NCI - Center for Cancer Research Bethesda, Maryland, United States, 20892 Frederick Cancer Research and Development Center Frederick, Maryland, United States, 21702-1201 收起 <<
NCT00006464	Unspecified Adult Solid Tumor,... 展开 >> Protocol Specific 收起 <<	Phase 1	Completed	-	United States, California ... 展开 >> USC/Norris Comprehensive Cancer Center and Hospital Los Angeles, California, United States, 90033-0804 City of Hope Medical Group Pasadena, California, United States, 91105 University of California Davis Cancer Center Sacramento, California, United States, 95817 United States, New Hampshire Norris Cotton Cancer Center Lebanon, New Hampshire, United States, 03756-0002 收起 <<
NCT00045747	Pancreatic Cancer	Phase 2	Completed	-	United States, New York ... 展开 >> Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10021 收起 <<
NCT00004059	Unspecified Adult Solid Tumor,... 展开 >> Protocol Specific 收起 <<	Phase 1	Completed	-	United States, New York ... 展开 >> Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10021 收起 <<
NCT00072267	Fallopian Tube Cancer ... 展开 >> Ovarian Cancer Primary Peritoneal Cavity Cancer 收起 <<	Phase 2	Completed	-	Canada, Ontario ... 展开 >> Margaret and Charles Juravinski Cancer Centre Hamilton, Ontario, Canada, L8V 5C2 Cancer Care Ontario-London Regional Cancer Centre London, Ontario, Canada, N6A 4L6 Ottawa Regional Cancer Centre Ottawa, Ontario, Canada, K1H 8L6 Princess Margaret Hospital Toronto, Ontario, Canada, M5G 2M9 收起 <<
NCT00098956	Extensive Stage Small Cell Lun... 展开 >>g Cancer Recurrent Small Cell Lung Cancer 收起 <<	Phase 2	Completed	-	Canada, Ontario ... 展开 >> Princess Margaret Hospital Phase 2 Consortium Toronto, Ontario, Canada, M5G 2M9 收起 <<
NCT00098956	-		Completed	-	-
NCT03207334	Acute Myeloid Leukemia	Phase 2	Withdrawn(Insufficient funding... 展开 >>) 收起 <<	January 2022	United States, Florida ... 展开 >> University of Florida Gainesville, Florida, United States, 32610 收起 <<
NCT01202877	-		Completed	-	-
NCT00030888	Kidney Cancer	Phase 2	Unknown	-	United States, California ... 展开 >> UCSF Comprehensive Cancer Center San Francisco, California, United States, 94115 Veterans Affairs Medical Center - San Francisco San Francisco, California, United States, 94121 收起 <<
NCT00004263	Leukemia Myel... 展开 >>odysplastic Syndromes 收起 <<	Phase 1	Completed	-	United States, Ohio ... 展开 >> Arthur G. James Cancer Hospital - Ohio State University Columbus, Ohio, United States, 43210 United States, Texas University of Texas - MD Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT00072189	Recurrent Melanoma ... 展开 >> Stage IV Melanoma 收起 <<	Phase 2	Terminated(Early termination f... 展开 >>or discouraging results) 收起 <<	-	United States, California ... 展开 >> UC Davis Cancer Center Sacramento, California, United States, 95817 收起 <<
NCT01174888	Acute Myeloid Leukemia ... 展开 >> Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities Adult Acute Myeloid Leukemia With Del(5q) Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) Adult Acute Myeloid Leukemia With t(15;17)(q22;q12) Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) Recurrent Adult Acute Myeloid Leukemia Secondary Acute Myeloid Leukemia 收起 <<	Phase 1	Completed	-	United States, Ohio ... 展开 >> The Ohio State University Medical Center Columbus, Ohio, United States, 43210 收起 <<
NCT00072189	-		Terminated(Early termination f... 展开 >>or discouraging results) 收起 <<	-	-
NCT00082017	Lymphoma, Large-Cell, Ki-1 ... 展开 >> Lymphoma, T-Cell 收起 <<	Phase 2	Terminated(IND was withdrawn b... 展开 >>y CTEP due to low accrual and cost of maintaining the IND.) 收起 <<	-	United States, Maryland ... 展开 >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 收起 <<
NCT00233454	Systemic Mastocytosis, Aggress... 展开 >>ive (ASM) Leukemia, Mast Cell Hematological Non-mast Cell Lineage Disease (AHNMD) 收起 <<	Phase 2	Completed	-	United States, California ... 展开 >> Stanford University School of Medicine Stanford, California, United States, 94305 United States, Massachusetts Dana Farber Cancer Institute Boston, Massachusetts, United States, 02115 United States, Missouri Washington University-St. Louis Saint Louis, Missouri, United States, 63110 收起 <<
NCT01202877	Leukemia	Phase 1 Phase 2	Completed	-	United States, Texas ... 展开 >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT00003289	Leukemia Lymp... 展开 >>homa Unspecified Adult Solid Tumor, Protocol Specific 收起 <<	Phase 1	Completed	-	United States, Maryland ... 展开 >> Johns Hopkins Oncology Center Baltimore, Maryland, United States, 21231 收起 <<
NCT00301938	Accelerated Phase Chronic Myel... 展开 >>ogenous Leukemia Adult Acute Megakaryoblastic Leukemia (M7) Adult Acute Minimally Differentiated Myeloid Leukemia (M0) Adult Acute Monoblastic Leukemia (M5a) Adult Acute Monocytic Leukemia (M5b) Adult Acute Myeloblastic Leukemia With Maturation (M2) Adult Acute Myeloblastic Leukemia Without Maturation (M1) Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) Adult Acute Myeloid Leukemia With t(15;17)(q22;q12) Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) Adult Acute Myelomonocytic Leukemia (M4) Adult Acute Promyelocytic Leukemia (M3) Adult Erythroleukemia (M6a) Adult Pure Erythroid Leukemia (M6b) Blastic Phase Chronic Myelogenous Leukemia Myelodysplastic/Myeloproliferative Neoplasms Previously Treated Myelodysplastic Syndromes Recurrent Adult Acute Lymphoblastic Leukemia Recurrent Adult Acute Myeloid Leukemia Relapsing Chronic Myelogenous Leukemia Secondary Acute Myeloid Leukemia T-cell Adult Acute Lymphoblastic Leukemia Untreated Adult Acute Lymphoblastic Leukemia Untreated Adult Acute Myeloid Leukemia 收起 <<	Phase 1	Completed	-	United States, Maryland ... 展开 >> University of Maryland Greenebaum Cancer Center Baltimore, Maryland, United States, 21201-1595 收起 <<
NCT00782067	Leukemia	Phase 2	Completed	-	-
NCT00782067	-		Completed	-	-
NCT01282502	Adenocarcinoma of the Rectum	Phase 1	Completed	-	United States, Massachusetts ... 展开 >> Massachusetts General Hospital Boston, Massachusetts, United States, 02114 Dana Farber Cancer Institute Boston, Massachusetts, United States, 02215 收起 <<
NCT00082017	-		Terminated(IND was withdrawn b... 展开 >>y CTEP due to low accrual and cost of maintaining the IND.) 收起 <<	-	-
NCT00866281	Acute Myeloid Leukemia ... 展开 >> Acute Lymphoblastic Leukemia 收起 <<	Phase 1 Phase 2	Terminated(Despite considerabl... 展开 >>e efforts to boost recruitment during the final year of the study, no new patients were enrolled.) 收起 <<	-	United States, Washington ... 展开 >> Seattle Children's Hospital CPKC412A2114 Seattle, Washington, United States, 98105 France Novartis Investigative Site Paris Cedex 19, France, 75935 Italy Novartis Investigative Site Genova, GE, Italy, 16147 Novartis Investigative Site Monza, MB, Italy, 20900 Novartis Investigative Site Roma, RM, Italy, 00165 Novartis Investigative Site Torino, TO, Italy, 10126 Netherlands Novartis Investigative Site Rotterdam, Netherlands, 3015 GJ Sweden Novartis Investigative Site Stockholm, Sweden, SE-171 76 收起 <<
NCT00866281	-		Terminated(Despite considerabl... 展开 >>e efforts to boost recruitment during the final year of the study, no new patients were enrolled.) 收起 <<	-	-
NCT01830361	Acute Myeloid Leukemia	Phase 2	Active, not recruiting	September 2020	Germany ... 展开 >> Klinikum Chemnitz gGmbH, Klinik für Innere Medizin III Chemnitz, Germany Universitätsklinikum Dresden Medizinische Klinik und Poliklinik I Dresden, Germany Marien Hospital Düsseldorf, Germany Universitätsklinikum Erlangen, Medizinische Klinik 5 Erlangen, Germany Klinikum der Johann-Wolfgang-Goethe Universität Frankfurt Main, Germany Universitätsklinikum Heidelberg Heidelberg, Germany Universitätsklinikum Jena, Klinik für Innere Medizin II Jena, Germany Universitätsklinikum Gießen und Marburg GmbH Marburg, Germany Universitätsklinikum Münster Münster, Germany Städtisches Klinikum Nord Nürnberg, Germany Klinikum der Universität Regensburg Regensburg, Germany 收起 <<
NCT01883362	Acute Myeloid Leukemia	Phase 2	Completed	-	-
NCT01429337	Hepatic Impairment	Phase 1	Recruiting	August 14, 2019	United States, Texas ... 展开 >> Novartis Investigator site Not yet recruiting Houston, Texas, United States, 77030 Novartis Investigator site Not yet recruiting San Antonio, Texas, United States, 78215 Belgium Novartis Investigative Site Terminated Bruxelles, Belgium, 1200 Bulgaria Novartis Investigative Site Recruiting Sofia, Bulgaria, 1618 Germany Novartis Investigative Site Terminated Berlin, Germany, 14050 Novartis Investigative Site Terminated Frankfurt, Germany, 60590 Lithuania Novartis Investigator site Not yet recruiting Kaunas, Lithuania, LT-50161 Poland Novartis Investigative Site Terminated Warszawa, Poland, 02 106 Romania Novartis Investigative Site Recruiting Cluj, Napoca, Romania, 400006 收起 <<
NCT02078609	AML and High Risk MDS	Phase 1	Recruiting	September 3, 2019	United States, Michigan ... 展开 >> Novartis Investigative Site Recruiting Ann Arbor, Michigan, United States, +1 48109 0944 Contact: Sabrina Pelton Hargrove +1 734 936 8538 sgomes@med.umich.edu Principal Investigator: Dale Bixby United States, Texas Novartis Investigative Site Recruiting Houston, Texas, United States, 77030 Australia, Victoria Novartis Investigative Site Recruiting Prahran, Victoria, Australia, 3181 France Novartis Investigative Site Completed Marseille, France, 13273 Germany Novartis Investigative Site Completed Ulm, Germany, 89081 Italy Novartis Investigative Site Recruiting Milano, MI, Italy, 20132 Novartis Investigative Site Recruiting Milano, MI, Italy, 20162 Novartis Investigative Site Recruiting Roma, RM, Italy, 00133 Japan Novartis Investigative Site Recruiting Shinagawa-ku, Tokyo, Japan, 141 8625 Netherlands Novartis Investigative Site Recruiting Amsterdam, Netherlands, 1081 HV 收起 <<
NCT01920204	Indolent Systemic Mastocytosis	Phase 2	Unknown	May 2015	Netherlands ... 展开 >> University Medical Center Groningen Groningen, Netherlands, 9700RB 收起 <<
NCT02634827	Acute Myeloid Leukemia With FL... 展开 >>T3/ITD Mutation Acute Myeloid Leukemia With Gene Mutations FLT3 Tyrosine Kinase Domain Point Mutation Secondary Acute Myeloid Leukemia Untreated Adult Acute Myeloid Leukemia 收起 <<	Phase 2	Active, not recruiting	April 15, 2020	United States, Minnesota ... 展开 >> Mayo Clinic Rochester, Minnesota, United States, 55905 收起 <<
NCT03114228	-		-	-	Canada, Ontario ... 展开 >> Novartis Investigative Site Hamilton, Ontario, Canada, L8V 1C3 Canada, Quebec Novartis Investigative Site Montreal, Quebec, Canada, H1T 2M4 收起 <<
NCT00233454	-		Completed	-	-
NCT03686345	Core Binding Factor Acute Myel... 展开 >>oid Leukemia (CBF-AML) 收起 <<	Phase 2	Active, not recruiting	December 31, 2025	Italy ... 展开 >> Ospedale Cà Granda - Niguarda S.C: Ematologia Milano, Italy, 20162 收起 <<
NCT02723435	Acute Myeloid Leukemia With Ge... 展开 >>ne Mutations Adult Acute Myeloid Leukemia in Remission 收起 <<	Phase 2	Withdrawn(Logistical and admin... 展开 >>istrative issues) 收起 <<	-	-
NCT02624570	-		-	-	-
NCT03379727	Acute Myeloid Leukemia	Phase 3	Recruiting	December 30, 2021	-
NCT00001444	Breast Cancer ... 展开 >> Lymphoma Neoplasm Prostatic Neoplasm 收起 <<	Phase 1	Completed	-	United States, Maryland ... 展开 >> National Cancer Institute (NCI) Bethesda, Maryland, United States, 20892 收起 <<
NCT01846624	Acute Myeloid Leukemia (AML) W... 展开 >>ith Multilineage Dysplasia Following Myelodysplastic Syndrome, in Adults AML (Adult) With 11q23 (MLL) Abnormalities AML (Adult) With Del (5q) AML (Adult) With Inv (16) (p13; q22) AML (Adult) With t (16;16) (p13; q22) AML (Adult) With t (8; 21) (q22; q22) Secondary AML (Adult) Untreated AML (Adult) 收起 <<	Phase 2	Terminated(Accrual factor)	-	United States, California ... 展开 >> Stanford University School of Medicine Stanford, California, United States, 94305 收起 <<
NCT01846624	-		Terminated(Accrual factor)	-	-
NCT01093573	Untreated Adult Acute Myeloid ... 展开 >>Leukemia 收起 <<	Phase 1 Phase 2	Unknown	-	United States, Ohio ... 展开 >> Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center Cleveland, Ohio, United States, 44106 United States, West Virginia West Virginia University Morgantown, West Virginia, United States, 26506 收起 <<

星形孢菌素 /Staurosporine {[allProObj[0].p_purity_real_show]}

Staurosporine 纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

Staurosporine 质控信息

Staurosporine 生物活性

Staurosporine 细胞研究

Staurosporine 动物研究

Staurosporine 临床研究

Staurosporine 参考文献

Staurosporine 实验方案

Staurosporine 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

星形孢菌素 /Staurosporine {[allProObj[0].p_purity_real_show]}

Staurosporine 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

Staurosporine 质控信息

Staurosporine 生物活性

Staurosporine 细胞研究

Staurosporine 动物研究

Staurosporine 临床研究

Staurosporine 参考文献

Staurosporine 实验方案

Staurosporine 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Staurosporine 纯度/质量文件产品仅供科研